Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/18521
Title
Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
Author(s)
Fernandez Rivera, Constantino | Calvo Rodríguez, María | Poveda, José Luís | Pascual, Julio | Crespo, Marta | Gomez, Gonzalo | Cabello Pelegrin, Sheila | Paul, Javier | Lauzurica, Ricardo | Perez Mir, Mònica | Moreso, Francesc | Perelló, Manel | Andres, Amado | González, Esther | Fernandez, Ana | Mendiluce, Alicia | Fernández Carbajo, Beatriz | Sanchez Fructuoso, Ana | Calvo, Natividad | Suarez, Alejandro | Bernal Blanco, Gabriel | Osuna, Antonio | Ruiz-Fuentes, M Carmen | Melilli, Edoardo | Montero Perez, Nuria | Ramos, Ana | Fernández, Beatriz | López, Verónica | Hernandez, Domingo | Better study
Date issued
2021-12-17
Language
Inglés
Document type
research article
Abstract
Multicenter, prospective, observational study to compare the relative bioavailability of once-daily tacrolimus formulations in de novo kidney transplant recipients. De novo kidney transplant recipients who started a tacrolimus-based regimen were included 14 days post-transplant and followed up for 6 months. Data from 218 participants were evaluated: 129 in the LCPT group (Envarsus) and 89 in the PR-Tac (Advagraf) group. Patients in the LCPT group exhibited higher relative bioavailability (Cmin /total daily dose [TDD]) vs. PR-Tac (61% increase; P
Subject
bioavailability | clinical practice | pharmacokinetics | renal transplantation | tacrolimus | treatment failure
MESH
Biological Availability | Drug Administration Schedule | Graft Rejection | Humans | Immunosuppressive Agents | Kidney Transplantation | Prospective Studies | Tacrolimus | Transplant Recipients
DOI
Collections
Full text access